We recently reported possible causes of resistance to EGFR TKIs in EGFR-mutant NSCLC patients: the high co-existence of the pretreatment somatic T790M mutation, with a clear impact on PFS, and the role of BIM mRNA expression as an independent prognostic marker.18 This evidence concerns the gene BCL2L11 and non-small cell lung carcinoma.